Literature DB >> 12607059

Management of 100 consecutive cases of pancreatic serous cystadenoma: wait for symptoms and see at imaging or vice versa?

Claudio Bassi1, Roberto Salvia, Enrico Molinari, Carlo Biasutti, Massimo Falconi, Paolo Pederzoli.   

Abstract

Pancreatic serous cystadenomas have a low malignancy rate. When nonsymptomatic, in selected patients, they can be managed without surgery; however, a high degree of diagnostic reliability is crucial. We admitted 100 consecutive cases (87 women with a median age of 51.86 years). Of these, 44 were symptomatic and 56 were diagnosed incidentally. Ultrasound correctly diagnosed 53% of the cases, incorrectly 31%, and was nondiagnostic in 16%. Computed tomography scan had similar rates (54%, 34% and 12%, respectively), while magnetic resonance imaging improved diagnostic accuracy to 74% and reduced incorrect diagnoses to 26%. In 21 cases, exploratory needle aspiration of the cyst was carried out; only 8 samples (38%) resulted in a diagnosis; in 12 patients (57%) insufficient material was acquired to allow for diagnosis, one case demonstrated epithelial dysplasia. In 1 patient an exploratory puncture resulted in a very serious bleeding. Sixty-eight patients were treated surgically, the 44 symptomatic cases and another 24 patients with ill-defined oligocystic lesions that could not be differentiated as serous or mucinous in the preoperative period. Two patients underwent resection because of frank tumor growth. In the two time periods analyzed (the first 7 years and the subsequent 6.5 years) the relationship between cases observed/operated on did not significantly change. Twenty-one (30.8%) distal pancreatectomies, 14 (20.5%) intermediate resections, 10 (14.7%) pancreaticoduodenectomies 4 (5.8%) enucleations, and 1 (1.4%) duodenum-preserving pancreatic head resection were carried out. Nine patients (13.2%), underwent exploratory laparotomy with a diagnostic biopsy. Another 9 underwent decompressive interventions with cystojejunostomies. The morbidity was 27.9%, with a reoperation rate of 7.3% and zero mortality. In general the patient's pain resolved in the postoperative period. Median follow-up was 43 months (range, 4-191 months). One patient died from other causes, and all others are currently alive. In the group of 32 patients who did not undergo operation, the median follow-up is 69 months (range, 8-164 months). Until more sophisticated technologies can be developed, the current diagnostic work-up will not result in increased preoperative diagnosis of serous-cystic tumors of the pancreas. This is mainly relevant to the oligocystic forms, which account for about one fourth of all serous tumors observed.

Entities:  

Mesh:

Year:  2003        PMID: 12607059     DOI: 10.1007/s00268-002-6570-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  45 in total

1.  Incidentally discovered benign pancreatic cystic neoplasms not communicating with the ductal system: MR/MRCP imaging appearance and evolution.

Authors:  R Manfredi; M Bonatti; M D'Onofrio; S Mehrabi; R Salvia; W Mantovani; R Pozzi Mucelli
Journal:  Radiol Med       Date:  2012-06-28       Impact factor: 3.469

2.  Cystic Neoplasm of the Pancreas.

Authors:  Alessandra Pulvirenti; Giovanni Marchegiani; Giuseppe Malleo; Alex Borin; Valentina Allegrini; Claudio Bassi; Roberto Salvia
Journal:  Indian J Surg       Date:  2015-10-28       Impact factor: 0.656

3.  Pancreatic Cyst Fluid Vascular Endothelial Growth Factor A and Carcinoembryonic Antigen: A Highly Accurate Test for the Diagnosis of Serous Cystic Neoplasm.

Authors:  Rosalie A Carr; Michele T Yip-Schneider; Scott Dolejs; Bradley A Hancock; Huangbing Wu; Milan Radovich; C Max Schmidt
Journal:  J Am Coll Surg       Date:  2017-05-18       Impact factor: 6.113

Review 4.  [Importance of endoscopy and endosonography for chronic pancreatitis and benign pancreas tumors].

Authors:  M Fuchs; W Schepp
Journal:  Radiologe       Date:  2008-08       Impact factor: 0.635

5.  Enhancing pancreatic mass with normal serum CA19-9: key MDCT features to characterize pancreatic neuroendocrine tumours from its mimics.

Authors:  Liang Zhu; Hua-Dan Xue; Wei Liu; Xuan Wang; Xin Sui; Qin Wang; Daming Zhang; Ping Li; Zheng-Yu Jin
Journal:  Radiol Med       Date:  2017-02-15       Impact factor: 3.469

Review 6.  Endoscopic ultrasound advances, part 1: diagnosis.

Authors:  Edward Kim; Jennifer J Telford
Journal:  Can J Gastroenterol       Date:  2009-09       Impact factor: 3.522

Review 7.  Does EUS-FNA molecular analysis carry additional value when compared to cytology in the diagnosis of pancreatic cystic neoplasm? A systematic review.

Authors:  Amy Gillis; Ilaria Cipollone; Grainne Cousins; Kevin Conlon
Journal:  HPB (Oxford)       Date:  2014-11-27       Impact factor: 3.647

8.  Is serous cystadenoma of the pancreas a model of clear-cell-associated angiogenesis and tumorigenesis?

Authors:  Duangpen Thirabanjasak; Olca Basturk; Deniz Altinel; Jeanette D Cheng; N Volkan Adsay
Journal:  Pancreatology       Date:  2008-12-13       Impact factor: 3.996

Review 9.  Cystic neoplasia of the pancreas: pathology and biology.

Authors:  N Volkan Adsay
Journal:  J Gastrointest Surg       Date:  2007-10-24       Impact factor: 3.452

10.  Cystic tumours of the pancreas.

Authors:  George Barreto; Parul J Shukla; Mukta Ramadwar; Supreeta Arya; Shailesh V Shrikhande
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.